SAN RAMON, Calif.–(Company WIRE)–Apr 29, 2021– BioVentrix, Inc., a privately held clinical unit enterprise focused on dealing with congestive coronary heart failure (CHF) via Transcatheter-dependent
SAN RAMON, Calif.–(Company WIRE)–Apr 29, 2021– BioVentrix, Inc., a privately held clinical unit enterprise focused on dealing with congestive coronary heart failure (CHF) via Transcatheter-dependent